You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

285 Results
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Nov 2017
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Neoadjuvant, Adjuvant, Palliative
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Sep 2019
Regimen
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - Single Agent - Indolent Lymphoma
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Nov 2019
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer
New Drug Funding Program
    Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    vanDETanib - Monotherapy for symptomatic and/or progressive medullary thyroid cancer (MTC), with specific criteria
Nov 2023
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    vemURAFenib - Monotherapy in patients with BRAF V600 mutation-positive unresectable stage Ill or stage IV melanoma, with specific criteria
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Mar 2025

Pages